Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Lexicon Pharmaceuticals Inc LXRX

Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LXRX)

Lexicon Pharmaceuticals to Participate in December Investor Conferences

GlobeNewswire 4 hours ago

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

GlobeNewswire 3 days ago

Lexicon Appoints Ivan H. Cheung to Board of Directors

GlobeNewswire 5 days ago

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago

GlobeNewswire 11 days ago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 13 days ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

GlobeNewswire November 6, 2024

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

GlobeNewswire November 5, 2024

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

GlobeNewswire November 5, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

GlobeNewswire November 4, 2024
View More News ››

Opinion & Analysis (NDAQ:LXRX)

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Streetwise Reports September 12, 2019
View More Opinion ››

Bullboard Posts (NDAQ:LXRX)

Lexicon to Reposition as Clinical Development-Focused Compan

Breaking News: $LXRX Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDAImplementing...
whytestocks - 3 days ago

Lexicon Pharmaceuticals Announces Strategic Repositioning to

JUST IN: $LXRX Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial PortfolioCompany to...
whytestocks - August 13, 2024

missed it by that much as

it was a bargain in the summer,another one on my watchlist,but you can't win them al,so glta.
coolfooldumbguy - January 2, 2020

Loss narrows and uptrend is born

LXRX moved above resistance and crossed its 50-day moving average.Next target SPlooks like $3Lexicon Pharmaceuticals Inc. reported fourth...
mart33 - March 24, 2008
View more Bullboard ››

Masivo Silver Corp.

Masivo Silver Corp.

Masivo Silver Corp. is a Canadian junior silver and gold mining exploration company based in Vancouver, Canada. The Company ...
View More »